Abstract
Metformin is a widely used oral antidiabetic drug with good tolerability. Recent studies suggest that it also possesses adjuvant potent anticancer properties in a variety of tumors. Neuroendocrine tumors (NETs) of the gastro-entero-pancreatic system (GEP) comprise a heterogeneous group of tumors with increasing incidence and limited effective therapeutic options. Here we report the antiproliferative effects of metformin in neuroendocrine tumor cells in vitro. Treatment of human pancreatic BON1, bronchopulmonary NCI-H727, and midgut GOT1 neuroendocrine tumor cells with increasing concentrations of metformin (0.1–10 mM) dose-dependently suppressed cell viability and cell counts. Metformin induced AMPK phosphorylation in pancreatic BON1 and midgut GOT1 but suppressed AMPK activity in bronchopulmonary NCI-H727. Thus, AMPK-dependent and AMPK-independent properties may be operative in NETs of different origin. Metformin suppressed mTORC1 signaling in all three tumor cell types, evidenced by suppression of 4EBP1, pP70S6K, and S6 phosphorylation, and was associated with compensatory AKT activity. We observed induction of ERK phosphorylation in BON1 and NCI-H727 and inhibition of ERK in midgut GOT1 cells, while all three tumor cell types responded with induction of GSK3 phosphorylation. This suggests a central role for GSK3 in metformin-mediated signal transduction. Inhibition of cell proliferation by metformin was associated with apoptosis induction only in midgut GOT1, evidenced by increased subG0/1 fraction and PARP cleavage. These results suggest a potential role of metformin as a (adjuvant) therapeutic for patients with NETs.
Article PDF
Similar content being viewed by others
References
Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F, 2010 Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9: 1092–1099.
Hawley SA, Ross FA, Chevtzoff C, et al, 2010 Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11: 554–565.
Zhou G, Myers R, Li Y, et al, 2001 Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167–1174.
Jalving M, Gietema JA, Lefrandt JD, et al, 2010 Metformin: taking away the candy for cancer? Eur J Cancer 46: 2369–2380.
Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S, 2011 Metformin: its emerging role in oncology. Hormones (Athens) 10: 5–15.
Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL, 2009 Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137: 482–488.
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC, 2011 Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20.
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D, 2012 Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18: 2905–2912.
Donadon V, Balbi M, Mas MD, Casarin P, Zanette G, 2010 Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30: 750–758.
Chen TM, Lin CC, Huang PT, Wen CF, 2011 Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 26: 858–865.
Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE, 2012 Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 97: 2347–2353.
Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M, 2012 The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 12: 410.
Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT, 2012 Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 135: 639–646.
Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL, 2010 Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy. Gynecol Oncol 116: 92–98.
Rattan R, Giri S, Hartmann LC, Shridhar V, 2011 Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15: 166–178.
Isakovic A, Harhaji L, Stevanovic D, et al, 2007 Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64: 1290–1302.
Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E, 2013 Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells. PLoS One 8: e57289.
Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, et al, 2011 In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 668: 373–382.
Brown KA, Samarajeewa NU, Simpson ER, 2012 Endocrine-related cancers and the role of AMPK. Mol Cell Endocrinol 366: 170–179.
Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D, 2008 Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 14: 5377–5384.
Modlin IM, Oberg K, Chung DC, et al, 2008 Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9: 61–72.
Pavel M, 2012 Translation of Molecular Pathways into Clinical Trials of Neuroendocrine Tumors. Neuroendocrinology 97: 99–112.
Raymond E, Dahan L, Raoul JL, et al, 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501–513.
Yao JC, Shah MH, Ito T, et al, 2011 Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514–523.
Pavel ME, Hainsworth JD, Baudin E, et al, 2011 Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378: 2005–2012.
Weber HC, 2013 Medical treatment of neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 20: 27–31.
Zitzmann K, De Toni EN, Brand S, et al, 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85: 54–60.
Larsson O, Morita M, Topisirovic I, et al, 2012 Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A 109: 8977–8982.
Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M, 2013 Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci 34: 126–135.
Dowling RJ, Niraula S, Stambolic V, Goodwin PJ, 2012 Metformin in cancer: translational challenges. J Mol Endocrinol 48: R31–43.
Zitzmann K, de Toni E, von Ruden J, et al, 2011 The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endoer Relat Cancer 18: 277–285.
Evers BM, Townsend CM Jr, Upp JR, et al, 1991 Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 101: 303–311.
Kölby L, Bernhardt P, Ahlman H, et al, 2001 A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol 158: 745–755.
Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF, 2012 Metformin and cancer therapy. Curr Opin Oncol 24: 103–108.
Auernhammer CJ, Goke B, 2011 Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60: 1009–1021.
Thakker RV, Newey PJ, Walls GV, et al, 2012 Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97: 2990–3011.
Tonelli F, Giudici F, Fratini G, Brandi ML, 2011 Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr Pract 17 Suppl 3: 33–40.
Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F, 2008 Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relar Cancer 15: 257–266.
Zitzmann K, Ruden J, Brand S, et al, 2010 Compensatory activation of Akt in response to mTOR and Raf inhibitors — a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295: 100–109.
Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM, 2011 Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 117: 4141–4154.
Meric-Bernstam F, Akcakanat A, Chen H, et al, 2012 PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18: 1777–1789.
Woodgett JR, 1994 Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin Cancer Biol 5: 269–275.
Woodgett JR, 2001 Judging a protein by more than its name: GSK-3. Sci STKE 2001:re12.
Ali A, Hoeflich KP, Woodgett JR, 2001 Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 101: 2527–2540.
Rasola A, Sciacovelli M, Pantic B, Bernardi P, 2010 Signal transduction to the permeability transition pore. FEBS Lett 584: 1989–1996.
Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A, 2009 Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156: 885–898.
Nolting S, Garcia E, Alusi G, et al, 2012 Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J Mol Endocrinol 49: 79–96.
Carvalho C, Correia S, Santos MS, Seica R, Oliveira CR, Moreira PI, 2008 Metformin promotes isolated rat liver mitochondria impairment. Mol Cell Biochem 308: 75–83.
Capano M, Crompton M, 2006 Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases. Biochem J 395: 57–64.
Gallo A, Ceolotto G, Pinton P, et al, 2005 Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes 54: 1123–1131.
Kefas BA, Cai Y, Kerckhofs K, et al, 2004 Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem Pharmacol 68: 409–416.
Dell’Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz MD, Morgan BW, 2009 Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med 54: 818–823.
Wilcock C, Bailey CJ, 1994 Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24: 49–57.
Marciello F, Del Preet, Marotta V, et al, 2014 Role of Metformin on Recurrence-Free Survival (RFS) in neuroendocrine Tumors (NET). ENETS 2014, Abstract M4.
Author information
Authors and Affiliations
Corresponding author
Additional information
Both authors contributed equally to this manuscript
Rights and permissions
About this article
Cite this article
Vlotides, G., Tanyeri, A., Spampatti, M. et al. Anticancer effects of metformin on neuroendocrine tumor cells in vitro. Hormones 13, 498–508 (2014). https://doi.org/10.14310/horm.2002.1517
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1517